U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT07547930) titled 'Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease' on April 14.
Brief Summary: Thyroid Eye Disease (TED), also known as Graves' orbitopathy, is an autoimmune condition that causes inflammation and tissue expansion behind the eyes, leading to bulging eyes (proptosis), double vision, and pain. Currently, intravenous glucocorticoids (steroids) are the standard first-line treatment. However, approximately 20-30% of patients do not respond to steroids, or cannot tolerate their side effects.
This study aims to evaluate the safety and efficacy of Tofacitinib, an oral medication known as a Janus kinase (JAK) ...